Technical Analysis for RLYB - Rallybio Corporaton
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 1.76 | 5.39% | 0.09 |
RLYB closed up 5.39 percent on Friday, April 19, 2024, on 16 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 7
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 50 DMA Resistance | Bearish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | 5.39% | |
| 50 DMA Resistance | Bearish | 5.39% | |
| MACD Bearish Signal Line Cross | Bearish | 5.39% | |
| Calm After Storm | Range Contraction | 5.39% | |
| Narrow Range Bar | Range Contraction | 5.39% |
| Alert | Time |
|---|---|
| 50 DMA Resistance | about 18 hours ago |
| 20 DMA Resistance | about 18 hours ago |
| Rose Above 20 DMA | about 19 hours ago |
| 60 Minute Opening Range Breakout | about 19 hours ago |
| Up 5% | about 19 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Rare Diseases Metabolic Disorders Severe And Rare Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Rare Diseases Metabolic Disorders Severe And Rare Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.14 |
| 52 Week Low | 1.225 |
| Average Volume | 1,935,294 |
| 200-Day Moving Average | 3.28 |
| 50-Day Moving Average | 1.80 |
| 20-Day Moving Average | 1.77 |
| 10-Day Moving Average | 1.90 |
| Average True Range | 0.29 |
| RSI (14) | 48.98 |
| ADX | 16.78 |
| +DI | 33.37 |
| -DI | 22.67 |
| Chandelier Exit (Long, 3 ATRs) | 2.58 |
| Chandelier Exit (Short, 3 ATRs) | 2.34 |
| Upper Bollinger Bands | 2.40 |
| Lower Bollinger Band | 1.13 |
| Percent B (%b) | 0.49 |
| BandWidth | 71.73 |
| MACD Line | 0.02 |
| MACD Signal Line | 0.03 |
| MACD Histogram | -0.0074 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.02 | ||||
| Resistance 3 (R3) | 2.01 | 1.91 | 1.97 | ||
| Resistance 2 (R2) | 1.91 | 1.85 | 1.92 | 1.96 | |
| Resistance 1 (R1) | 1.84 | 1.81 | 1.88 | 1.85 | 1.94 |
| Pivot Point | 1.74 | 1.74 | 1.76 | 1.75 | 1.74 |
| Support 1 (S1) | 1.67 | 1.68 | 1.71 | 1.68 | 1.58 |
| Support 2 (S2) | 1.57 | 1.64 | 1.58 | 1.56 | |
| Support 3 (S3) | 1.50 | 1.57 | 1.55 | ||
| Support 4 (S4) | 1.51 |
